Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Bratislava Medical Journal Vol.115, No.4, p.233-237, 2014 |
||
Title: A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer | ||
Author: C. T. Sun, X. Xu, W. Sheng, X. W. Wang, S. L. Wen, J. Q. Han | ||
Abstract: Purpose: This meta-analysis investigated pemetrexed-based doublet compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer. Meta-analysis demonstrated that pemetrexed-based doublet arm significantly improved the overall response rate (OR=2.70, 95% CI: 1.76–4.15, p=0.000), compared with docetaxel alone group, while there were no significant differences in overall survival (HR=0.88, 95% CI: 0.74–1.04, p=0.132), progression-free survival (HR=0.91, 95% CI: 0.73–1.15, p=0.443), and 1-year survival rate (OR=1.43, 95% CI: 0.85–2.40, p=0.178) between the two arms. However, there were more frequencies of grade 3–4 leucopenia (OR=2.86, 95% CI: 1.32–6.20, p=0.008), neutropenia (OR=2.69, 95% CI: 1.55–4.68, p=0.000) and thrombocytopenia (OR=6.92, 95% CI: 2.51–19.07, p=0.000) in pemetrexed-based doublet group. Grade 3–4 anemia (OR=0.62, 95% CI: 0.33–1.18, p=0.144) and fatigue (OR=1.15, 95% CI: 0.73–1.79, p=0.550) had equivalent incidences in the two groups.
|
||
Keywords: non-small-cell lung cancer, docetaxel, second-line therapy, meta-analysis. | ||
Year: 2014, Volume: 115, Issue: 4 | Page From: 233, Page To: 237 | |
doi:10.4149/BLL_2014_048 |
||
|
![]() |
|